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Abstract
Telogen effluvium (TE) is a noninflammatory disease characterized by diffuse loss of 
telogen hair. It is the most frequent cause of diffuse hair loss and the actual incidence of 
the disease is not known. According to the underlying etiology, TE could be physiologi-
cally and pathologically classified. The evaluation of a patient with TE includes a detailed 
history, physical examination, and laboratory tests. The patients should be questioned in 
terms of TE subtype, duration, and clinical course of hair loss. The most important point 
in the treatment of TE is to consult about the natural course of the disease.
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1. Introduction
Hair is important for social communication and healthy appearance, and acts as marker for iden-
tity of one’s personal image. It can be, indeed, directly related to a feminine appearance, sexual-
ity, attractiveness, and the concept of personality in females. In addition, hair is the second fastest 
growing tissue of the body, followed by bone marrow. Therefore, many metabolic derangements 
can be manifested with alopecia, and hair loss may be the initial clinical sign of a systemic disease 
[1]. Although hair loss may cause anxiety in individuals, irrespective of age and sex, and results 
in reduced quality of life and restriction of social relations in females, more than males. As a 
result, hair loss is the most frequent cause of admission to dermatology clinics [2].
2. Definition
Telogen effluvium (TE) was first termed by Kligman to define an increased shedding of nor-
mal club hairs based on the hypothesis that, irrespective of the cause, the follicle tends to act in 
a similar manner undergoing a premature termination of anagen and precipitating telogen [3].
© 2017 The Author(s). Licensee InTech. This chapter is distributed under the terms of the Creative Commons
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Telogen effluvium is a noninflammatory disease characterized by diffuse loss of telogen hair, 
caused by any disruption of hair cycle which leads to increased and synchronized telogen 
shedding [4]. It is the leading cause of diffuse hair loss. However, the actual incidence of the 
disease remains unknown [2]. It has been suggested to result from an abrupt shift of large 
numbers of anagen hairs to telogen hairs on the scalp with altered ratio of anagen hair to telo-
gen hair from the normal ratio of 90:10–70:30 [1]. The degree of telogen effluvium depends on 
the severity and duration of exposure, but not the type of the agent [5].
Although the effect of age also remains unclear; elderly women are reported to be more vulner-
able to acute TE following high fever, surgical trauma, severe hemorrhage, or immense psy-
chological stress. In children, TE is responsible for only a minority of cases with hair loss [6, 7].
Telogen effluvium can be classified into two groups, according to the duration of disease, as 
acute and chronic. The duration of disease is shorter than 6 months in acute TE, while it takes 
more than 6 months in chronic state. In acute TE, hair loss typically begins 2–3 months later than 
the triggering event, although the triggering factor is unknown in 33% of the cases. However, 
chronic TE is frequent in healthy females in the fourth to fifth decades [7]. In addition, telogen 
gravidarum is a variant of TE which follows childbirth. Significant telogen gravidarum can 
affect a third to a half of all women following childbirth [8]. In postpartum TE, follicles remain 
in a prolonged anagen phase, rather than cycling into the telogen phase. Once released from 
anagen, an increased shedding of telogen hair is one of the clinical signs of the disease [9].
3. Epidemiology
The majority of TE is subclinical; however, its actual incidence or prevalence still remains 
unclear. It has no predilection for particular racial or ethnic groups. Although it affects both 
sexes, women are more likely to present for the evaluation of acute TE than men [10]. A higher 
number of women also suffer from chronic TE than men. Chronic TE, which is less common 
than the acute variant, mostly affects women between the ages of 30 and 60 years [11, 12].
4. Etiology and pathogenesis
The cycle of hair follicle includes anagen, catagen, and telogen phases. In a normal scalp, about 
90–95% of the hair follicles are in the anagen phase, 5–10% are in the telogen phase, and a loss of 
100–150 hairs per day is accepted as normal. Telogen effluvium is an abnormality of hair cycling 
during which a higher percentage of the scalp hairs are in the telogen phase. In TE, the number 
and ratio of hair follicles in the telogen phase increase. The physiological daily shedding of 
about 100–150 telogen club hair from the scalp is a usual nature of the hair cycle. In addition, 
follicles normally retain telogen hair, until the reentry to the anagen phase. Eventually, a new 
anagen hair pushes the old telogen hair out. It is unlikely to result in visible alopecia and to alter 
the trichogram [13]. Temporary alopecia may develop, since the shorter telogon hair is replaced 
by the long telogen hair. When the new anagen hair grows within 3–6 months, alopecia resolves 
[7]. In addition, no genetic cause for TE has been proposed to date [2, 9].
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According to the underlying etiology, TE can be physiologically and pathologically catego-
rized. Physiological causes include neonatal and physiological TE. However, pathological 
causes of TE include inflammatory diseases, stress, drugs, endocrine disorders, organ dys-
functions, nutritional causes, exogenous factors, syphilis, and systemic lupus erythematous 
[2]. The main causes of TE are shown in Table 1 [2, 10].
Acute telogen effluvium
Acute or chronic major illness
Collagen vascular disease
Febrile illness:
-HIV infection
-Malaria
-Tuberculosis
-Typhoid
Major surgery
Endocrine disorders:
-Hypothyroidism
-Hyperthyroidism
Nutritional:
-Protein or caloric dietary restriction
-Nutritional deficiencies
-Iron deficiency anemia
-Congenital or acquired zinc deficiency
-Rapid weight loss
Drugs, supplements, or toxins
Physiological:
-Telogen gravidarum
-Physciological effluvium of newborn
Significant emotional stress
Inflammatory conditions of the scalp (e.g., seborrheic dermatitis)
Infectious conditions that affect the scalp (e.g., fungal, bacterial, or spirochetal)
Chronic telogen effluvium
Shortened anagen
May follow acute TE or telogen gravidarum
Chronic diffuse telogen haır loss
Thyroid disorders
Iron deficiency anemia
Acrodermatitis enteropathica
Crash dieting
Chronic starvation
Hypoproteinaemia
Metabolic disturbances
Advanced malignancy
Senility
Systemic lupus erythematosus
Dermatomyositis
Syphilis
Drugs
HIV infection
Anorexia nervosa
HIV: human immunodeficiency virus, TE: telogen effluvium
Table 1. Causes of telogen effluvium [2, 10].
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5. Functional types of telogen effluvium
Headington defined five types of functional TE, according to the different follicular cycles. 
These include the immediate anagen release, delayed anagen release, immediate telogen 
release, delayed telogen release, and short anagen phase [2].
5.1. Immediate anagen release
It is a common form of TE which is related to physiological stress, severe illness, and drug use. 
During stress, the cytokines induce apoptosis of hair follicle keratinocytes, first with catagen, 
followed by telogen [2]. Therefore, follicles, which are induced to leave the anagen, enter 
telogen early [14].
5.2. Delayed anagen release
It typically occurs in women with postpartum hair loss, and when the oral contraceptives are 
discontinued. It is also known as telogen gravidarum. It is caused by high levels of circulat-
ing placental estrogen, which prolongs the anagen phase, result in a full head of hair during 
pregnancy. The withdrawal of these hormones during delivery stimulates the overdue ana-
gen hair to enter into the catagen phase simultaneously. As a result, an increased shedding of 
telogen hair can be seen after a couple of months of delivery [2, 15].
5.3. Immediate telogen release
Drug-induced shortening of telogen results in follicles with the reentry of the anagen pre-
maturely [14]. Hair follicles typically release the club hair 100 days later. It is caused by a 
shortened normal telogen cycle. This type of hair shedding usually occurs 2–8 weeks, fol-
lowing therapy with topical minoxidil [16]. As the exogen hair at resting is released, this 
paradoxical phenomenon occurs, by stimulated anagen phase [2].
5.4. Delayed telogen release
Hair follicles do not shed or recycle into anagen, but remain in prolonged telogen. When 
teloptosis defined as the termination of telogen phase with hair shedding occurs, the main 
clinical manifestion of increased shedding of the club hair presents. In such cases, the major 
cause is seasonal hair loss [2, 16].
5.5. Short anagen phase
Idiopathic shortening of anagen duration results in persistent telogen shedding. The condi-
tion is not associated with the hair shaft fragility or hair unruliness. It leads to resistant and 
chronic TE. It is common in hereditary hypotrichosis and ectodermal dysplasia and as an 
isolated disorder in otherwise healthy children [2, 16].
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6. Clinical findings
6.1. Acute telogen effluvium
Women with acute TE are usually admitted with complaints of increased hair loss while 
washing hair and combing or brushing hair. These patients often have a concern of baldness. 
Despite excessive hair shedding, the density of the hair is visible [14]. If the main triggering 
cause of TE is eliminated, hair loss lasts for up to 6 months [1].
In the absence of a concomitant hair or scalp disorder, the scalp and hair shafts seem normal 
without any symptoms. In TE, the distribution of the scalp hair loss is diffuse; however, the 
bitemporal area may be the most affected area [10, 11]. In general, patients do not relate these 
events to their recent illness and have a concern of baldness [7]. In addition, no scarring or 
inflammation is present [2, 13].
To date, several factors have been suggested to be associated with the induction of TE, depend-
ing on clinical observations. However, there is no data to confirm and define the level of risk 
for TE related to these factors. It is estimated that an inciting factor is unable to be detected in 
about one-third of patients with acute TE [10].
In postpartum TE, time to hair loss often takes 2 or 3 months after delivery, although it can 
be delayed up to 6 months, depending on the length of the telogen phase. More interestingly, 
TE can be more pronounced, if delivery occurs in the fall, as the time of postpartum TE coin-
cides with an increased seasonal hair shedding during the winter. In addition, breastfeeding 
may partially reduce TE with the effects of prolactin, since lactating women have an increased 
anagen-to-telogen ratio at 4 months in the postpartum period, compared to the nonlactating 
women. The condition often resolves by 12 months after delivery, even if breastfeeding contin-
ues [14, 17].
6.2. Chronic telogen effluvium
Women with chronic TE usually suffer from a prolonged, fluctuating course of TE for more 
than 6 months. In general, there is no trigger factor; however, some patients may have a con-
tinuation of acute TE with a shortened anagen phase, underlying a complaint of shortened 
hair as well as hair shedding seen in all patients with TE [13, 14].
In some cases, this type of hair loss may last for several years. Prolonged TE may be caused by 
multiple sequential triggers, although no trigger is identified in certain cases [1, 12].
In primary chronic TE, there is no specific triggering agent. Chronic TE can be induced by 
an acute TE [16]. Both hypothyroidism and hyperthyroidism are associated with chronic 
diffuse telogen hair loss (CDTHL). This is usually reversible upon reestablishment of the 
euthyroid state, although at times, longstanding hypothyroidism may cause hair follicle 
atrophy [18].
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Iron deficiency anemia is also a causative factor of CDTHL, since follicles need iron to stim-
ulate the anagen phase of the hair cycle [19]. The hair loss can be reversed with the iron 
supplementation. Iron deficiency without anemia is more controversial, as it has a poten-
tial relationship with CDTHL [20]. In the majority of cases, drug-induced CDTHL occurs 
mechanistically via the immediate anagen release [19]. It typically occurs within 6–12 weeks 
of treatment and progresses while on the medication. It, then, begins to resolve after the dis-
continuation of the drug [21]. To the best of our knowledge, no controlled trials showing a 
causal relationship for specific medications have been conducted; however, if a medication is 
suspected, it should be discontinued for a period of at least 3 months to examine its possible 
link to the hair loss [4, 14].
Moreover, diet is associated with the hair condition. Therefore, each patient should be ques-
tioned for the protein intake. Eating disorders can also lead to hair loss. In a study, 67% of the 
patients with TE had bulimia, while 61% had anorexia nervosa [22].
7. Diagnosis
In the presence of hair loss, the key step is taking a thorough history of the patient. In addi-
tion, the affected areas of the scalp should be examined to determine the presence or absence 
of follicular orifices. It helps to distinguish the scarring and nonscarring alopecia [23]. In the 
presence of follicular orifices, nonscarring alopecia can be suspected, although further history 
findings are useful to unveil the main cause [14].
The diagnosis of TE is usually based on the patient’s history, physical examination findings, 
and hair pull test results (Table 2) [10]. The recognition of diffuse, noninflammatory, non-
scarring hair loss should raise the clinical suspicion for TE, when it occurs acutely and is 
preceded by a physiological or psychological stressor, in particular. In the majority of cases, 
scalp biopsy is not required [10].
Anamnesis, clinical diagnosis
Hair pull test
Trichogram
Light microscoby
Biopsy
Laboratory evaluation
Wash test
Table 2. Diagnosis of telogen effluvium [10].
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8. Histopathology
With the exception of TE induced by inflammatory disorders affecting the scalp, scalp biopsies 
of TE not show an inflammation. On the other hand, increased telogen follicles are the main 
histopathological finding [24]. Unlike androgenetic alopecia, the rate of vellus hair follicles 
does not increase [12].
9. Evaluation
Patients with TE should be evaluated with a detailed history, physical examination, and labo-
ratory tests (Table 3) [1]. In addition, TE subtype, duration, and clinical course of hair loss 
should be also questioned. In particular, possible triggering factors within 2–5 months before 
hair loss begins should be addressed [7]. In the absence of no causative factor, a complete 
blood count, serum ferritin, biochemical markers, and thyroid function tests should be per-
formed [2].
In addition, hair-care practices of patients which may damage hair such as braiding lead-
ing to traction alopecia, and the loss of eyelashes, eyebrows, and axillary, pubic, or body 
hair should be questioned, as alopecia areata or trichotillomania may affect any hair-bear-
ing area. A detailed history, childbirth, prior surgeries, and psychosocial stress should be 
also assessed. Furthermore, drugs that may cause TE should be examined (Table 4) [1, 2]. 
Additionally, acne, irregular menstrual cycles, or hirsutism may indicate androgen excess, 
which contributes to female pattern hair loss. Symptoms of hyperthyroidism or hypothy-
roidism should be also evaluated and current and previous medications should be care-
fully reviewed. A history of following a strict vegetarian diet or heavy menses may suggest 
iron deficiency anemia [1].
Duration
Thinning, shedding
Localization: localized diffuse
Associated symptoms: itching, pain, burning
Systemic symptoms, personal history
Nutritional history
Drug history
Psychosocial history
Hair care products-cosmetics history
Family history
Table 3. History of hair loss checklist [1].
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10. Laboratory
Although the majority of female patients with hair loss have normal laboratory test results, 
a complete blood count, ferritin, thyroid-stimulating hormone, antinuclear antibody titer, 
and vitamin D level can be studied, as abnormal levels of these parameters are likely to be 
associated with distinct forms of alopecia. In addition, serum and free testosterone, dehydro-
epiandrosterone sulfate, and prolactin should be analyzed, in the presence of any signs of 
potential endocrine abnormalities including severe acne, hirsutism, virilization, galactorrhea, 
menstrual irregularities, or infertility [14]. In case of any risk factors for syphilis, the venereal 
disease research laboratory test is recommended [1].
The link between serum levels of ferritin or vitamin D and TE is controversial. To date, studies 
investigating the relationship between serum ferritin levels and TE have shown controversial 
results [20, 25–27].
Iron deficiency anemia and thyroid disorders are the common conditions associated with TE. 
However, in the majority of cases, no apparent clinical features suggesting these conditions 
are observed [2].
A strict vegetarian diet or heavy menses may be suggestive for iron-deficiency anemia. Iron 
supplementation is recommended for TE patients who have had a serum ferritin level less 
than 70 ng per milliliter [20]. However, the effects of iron supplementation for TE have not 
been extensively investigated in controlled trials. The efficacy data are limited to case series, 
indicating cessation of hair loss and new hair growth with iron supplementation in women 
with low ferritin levels. On the other hand, the beneficiary effect of iron supplementation has 
not been established in all cases [27, 28].
More than 5%: 1–5%: Less than 1%
Mood stabilizers (lithium and valproic acid): the most common Oral contraceptives Amiodarone
Antidepresants (fluoxetine) Acyclovir Amitriptyline
Oral retinoids (acitretin, isotretinoin) Allopurinol Azathioprine
Anticoagulant (heparin,enoxaparine, warfarin) Buspirone Dopamine
Antimicrobial (isoniazid) Captopril Naproxen
Antiviral (indinavir) Carbamazepine Omeprazole
Interferon alpha Cyclosporine Paroxetine
Terbinafine Lamotrigine Sertraline
Beta-blockers (metaprolol, propronolol) Nifedipine Verapamile
Hypolipidemic drugs Venlafaxine
Cetirizine Vinblastine
Gold Vincristine
Table 4. Drugs associated with telogen effluvium [1, 2].
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Furthermore, perimenopausal symptoms such as hot flashes and irregular bleeding should be 
evaluated in older women. In this age group, starting or interrupting hormonal replacement 
therapies should be ruled out as a possible cause of TE [29].
11. Physical examination
The scalp hair and scalp skin should be carefully examined in all patients. Scale, inflammation, 
pustules, and scarring or abnormalities of the hair shaft should not be evaluated as the manifes-
tations of an isolated TE. On physical examination, the entire skin surface should be examined to 
identify the extent of hair loss and to detect the main features of other hair or scalp disorders [10].
11.1. Hair pull test
A hair pull test should be performed as part of the physical examination in patients with 
suspected TE. The test is helpful to detect active hair shedding. About 50–60 hair fibers close 
to the skin surface are grasped and the hairs from the proximal to distal ends are tugged. 
Normally, only two or three hairs are pulled out by this method. In the presence of abnormal 
shedding, more than 10% hair (6–10 hair) can be easily pulled out from any part of the scalp, 
if the patient has not shampooed for more than 24 h [2, 30]. The test should be performed in 
four regions of the scalp: the frontal, occipital, and both temporal regions. The hair should not 
be shampooed for at least a day [29]. Light microscope is used to examine the hair shafts and 
to confirm that the loose hairs are telogen hairs [10].
Of note, the hair pull test may produce a false-negative result, if the patient has shampooed or 
vigorously groomed the hair on admission. In addition, if the patient has not shampooed or 
combed the hair for several days, the test may yield false positivity [10].
11.2. Trichogram (hair pluck test)
From a hair pluck, sample is abnormal, which indicates higher than 25% telogen hair [13]. 
Since telogen rate in this test is not associated with the severity of the hair loss, the sensitivity 
of the hair pull test is low [2].
11.3. Wash test
As daily hair count is troublesome, the wash test has been proposed. In wash test, the patient 
is instructed to wash hair after 5 days of last shampoo in a sink with its drain covered by 
gauze. The hair entrapped in the gauze is, then, counted [2].
11.4. Dermoscopy
Data relating to the dermoscopic findings of TE are limited. Acute TE may indicate empty fol-
licles and regrowing hairs of normal thickness (>0.03 mm). Dermoscopic findings are useful to 
distinguish chronic TE from female pattern hair loss (female androgenetic alopecia). The latter 
variably exhibits a greater hair diameter [31].
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11.5. Wood's light examination
TE can be due to seborrheic dermatitis of the scalp. On physical examination, a greasy scale 
and erythema on the scalp can be seen with a characteristic distribution. In addition, examina-
tion with a Wood’s lamp (a source of ultraviolet A light) can be useful for the definite diagno-
sis of seborrheic dermatitis, which unveils the scale [32].
11.6. Procedures
In the majority of cases, further investigation is not required, beyond the clinical history and 
physical examination. However, additional diagnostic tools can be useful in patients in whom 
the diagnosis remains unclear [10].
11.7. Scalp biopsy
In most cases, scalp biopsies are not required and are only reserved for certain patients with 
an obscure diagnosis. Although scalp biopsy is not mandatory, it helps to exclude female 
pattern hair loss and alopecia areata. In general, biopsy results are normal, except increased 
telogen follicles (normal telogen counts vary between 6 and 13%). The rate of telogen follicles 
more than 15% indicates TE, while more than 25% is the major manifestation of TE [2, 30].
A 4-mm punch biopsy is sectioned horizontally for each specimen, and a second specimen 
is sectioned vertically. In general, we perform biopsy in an area outside of predilection for 
androgenetic alopecia to reduce the possibility of diagnostic uncertainty; therefore, we avoid 
bitemporal, frontal, and vertex areas of the scalp, if applicable. We usually select the leading 
edge of the alopecic area and avoid completely bald areas [10].
11.8. Trichograms and phototrichograms
Although these techniques are less common, they may be helpful to confirm the diagnosis of 
TE. With the use of these techniques, the rate of telogen and anagen hair follicles on the scalp 
can be evaluated. Currently, trichograms and phototrichograms are mostly used in special-
ized clinical hair centers and research studies. These procedures are described in detail in a 
separate section [10].
12. Differential diagnosis
The pattern of hair thinning or shedding can be helpful in the differential diagnosis. Diffuse 
thinning of the scalp hair in both temporal regions is highly suggestive of TE [33]. Frontal 
fibrosing alopecia almost particularly affects the frontal and frontotemporal hairlines. In case 
of traction alopecia, the periphery of the scalp is usually affected. Central centrifugal cica-
tricial alopecia (CCCA) typically begins at the vertex of the scalp, expanding centrifugally 
[34]. Alopecia areata may present in varying patterns. The patchy type is usually localized, 
whereas a more diffuse pattern has also been described [29, 35].
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13. Treatment
Consulting on the natural course of the disease is the mainstay of the treatment of TE. 
A detailed evaluation should be performed to identify the underlying cause. In general, 
hair loss halts within 3–6 months in patients in whom a triggering factor is identified and 
eliminated [2].
Although spontaneous improvement is expected for patients with TE related to an isolated 
event such as childbirth, those related to a persisting insult should have the cause eliminated 
or treated, if applicable. In case of drug-induced TE, the suspected drug should be discontin-
ued for at least 3 months to identify whether hair loss improves with the discontinuation of 
therapy. In addition, concomitant hair or scalp disorders such as seborrheic dermatitis should 
be simultaneously treated [10].
Furthermore, hair loss may profoundly affect the psychosocial status of the patient, irrespec-
tive of the degree of hair loss. Therefore, emotional well-being of the patient is critical in the 
management. All concerns of the patient should be sensitively addressed by the clinician. In 
addition, patients should be educated on the hair growth cycle and the expected course of TE, 
including an explanation that complete hair loss is not expected to occur, to reassure patients. 
Follow-up is also helpful both to encourage the patient and to identify those requiring further 
evaluation for persistent TE [10].
Moreover, the diagnosis and treatment of TE should be briefly discussed with the patient. 
Potential therapeutic options include the followings, based on the pathogenesis of TE:
1. Inhibition of catagen.
2. Induction of anagen in telogen follicles.
3. Inhibition of exogen.
Currently, no potent, FDA-approved catagen inhibitors or anagen inducers are commercially 
available. However, catagen-inducing drugs such as beta-blockers, retinoids, anticoagulants, 
or antithyroid drugs should be avoided and catagen-inducing endocrine disorders including 
thyroid dysfunction, hyperandrogenism, or hyperprolactinaemia should be simultaneously 
treated. Replacement therapy for catagen-promoting deficiencies such as iron, zinc, estradiol, 
or proteins can be also prescribed [2].
Today, no proven vitamins or supplements for any form of hair loss are commercially available. 
In case of a measurable deficiency such as iron-deficiency anemia, replacement therapy may 
be initiated. However, a balanced diet and stable body weight are the critical measures. In the 
literature, biotin supplementation has been shown no effect on TE [36]. Despite their claimed 
benefits, there are no controlled studies investigating the efficacy of iron or thyroxine replace-
ment on TE [4]. In addition, maintaining serum ferritin above 40 ng/dL has been suggested to 
reverse hair loss [26]. In case of poor response, possible factors such as poor compliance, misdi-
agnosis, malabsorption, coexisting anemia, or persistent blood loss should be considered. Iron 
supplementation should be continued for 3–6 months, until the iron stores are replenished [37]. 
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Of note, unnecessary long-term iron supplementation may result in iron overload [38]. On the 
other hand, there is no proven effect of antioxidants or other supplements on TE [39].
14. Conclusion
In conclusion, TE is a common disease that causes diffuse hair loss. The diagnosis of acute 
TE is based on patient’s history and examination findings. Since acute TE is self-limiting, the 
clinician should monitor the patient, until spontaneous resolution. However, in case of severe 
or prolonged shedding, further investigations are warranted. On the other hand, chronic TE 
can be only diagnosed, after other causes of chronic diffuse telogen hair loss are ruled out. 
There is no specific treatment for TE. In the management of TE, the major aspect is to educate 
the patient relating to the natural history of the condition.
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